2 results match your criteria: "University of OsloOslo 0379[Affiliation]"
Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study.
Am J Cancer Res
September 2016
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityHenan, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University HospitalOslo 0424, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
Ovarian cancer is the most lethal gynecologic malignancy, in which cancer stem cells (CSC) have been reported to be the driving force of relapse and therapy-resistance. It is therefore important to explore CSC markers in ovarian cancer. This project aimed to explore the correlation between the expression of potential CSC maker Cacna2d1 and clinicopathological parameters in 238 epithelial ovarian cancer (EOC) samples.
View Article and Find Full Text PDFDecreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma.
Am J Cancer Res
September 2016
Department of Oncology, The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052, Henan Province, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, University of OsloMontebello, Oslo 0379, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
Pyruvate dehydrogenase A1 (PDHA1) serves as a gate-keeper enzyme link between glycolysis and the mitochondrial citric acid cycle. The inhibition of PDHA1 in cancer cells can result in an increased Warburg effect and a more aggressive phenotype in cancer cells. This study was conducted to investigate the expression of PDHA1 in ovarian cancer and the correlation between PDHA1 expression and the prognosis of patients.
View Article and Find Full Text PDF